
Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases
Episode 194
Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he’s leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing symptoms. In this episode, Patrick walks us through his personal journey into science, the company’s DIAGONAL platform, and their lead program DIAG723, which recently received Orphan Drug Designation for the rare disease HHT, and is advancing toward the clinic. We also discuss Diagonal’s oversubscribed $125 million Series B financing that closed in January 2026, and what clustering antibodies could mean for patients with HHT, pulmonary arterial hypertension, and beyond. 01:33 Meet Patrick Andre 08:01 Diagonal’s mission 11:39 What are clustering antibodies 16:05 Receptor clustering benefits for HHT and PAH 20:24 Preclinical data on preventing and reversing HHT pathology 22:39 The impact of the $125 Million Series B financing round Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Publisher
Beyond Biotech - the podcast from Labiotech
Published
April 24, 2026
Duration
31 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Labiotech
Beyond Biotech - the podcast from Labiotech
@beyondbiotechthepodcastfroml
#diagonaltherapeuticsinnovative #vasculardiseases
